Location History:
- Palo Alto, CA (US) (1985 - 1988)
- Chapel Hill, NC (US) (1989)
- Chapel, NC (US) (1990)
- Durham, NC (US) (1990 - 1992)
- Chaple, NC (US) (1997)
Company Filing History:
Years Active: 1985-1997
Title: The Innovative Contributions of Arthur E. Frankel
Introduction
Arthur E. Frankel is a distinguished inventor based in Durham, NC, recognized for his significant contributions to the field of biomedical research. With a total of 9 patents to his name, his work particularly focuses on the development of monoclonal antibodies for combating human breast cancer. His innovative approach and dedication to improving cancer diagnostics and treatment have marked him as a prominent figure in his domain.
Latest Patents
Among his latest patents, Frankel has developed monoclonal anti-human breast cancer antibodies. These murine monoclonal antibodies are meticulously prepared and characterized to selectively bind to high molecular weight mucins through immunoprecipitation tests. These antibodies are classified as either IgGs or IgMs. His innovative work also includes the production of immunotoxins that couple the monoclonal antibodies with a cytotoxic moiety. Furthermore, he has created murine monoclonal antibodies or fragments thereof that specifically target human breast cancer cells. When these antibodies are conjugated to ricin A chain, they exhibit a significant TCID 50% against various human breast cancer cell lines, showing a potency of less than about 10 nM.
Career Highlights
Arthur E. Frankel has had a notable career, contributing extensively to the field of cancer research. He has served in key positions at Cetus Corporation and Cetus Oncology Corporation, where he was directly involved in groundbreaking research and innovation in oncology.
Collaborations
During his career, Frankel has collaborated with esteemed colleagues, including David B. Ring and Michael J. Bjorn. These partnerships have been instrumental in enhancing the scope and impact of his research, facilitating advancements in the understanding and treatment of breast cancer.
Conclusion
In conclusion, Arthur E. Frankel's contributions to the field of cancer research, particularly through the creation of targeted monoclonal antibodies, have had a lasting impact on the way breast cancer is diagnosed and treated. His innovative spirit and collaboration with fellow scientists continue to inspire progress in biomedical sciences, highlighting the importance of research and innovation in improving patient outcomes.